Thrombosis Research
Volume 124, Issue 4 , Pages 397-402 , September 2009

Prothrombotic factors and the risk of acute onset non-cardioembolic stroke in young Asian Indians

  • Arijit Biswas

      Affiliations

    • Department of Hematology
    • ,
  • Ravi Ranjan

      Affiliations

    • Department of Hematology
    • ,
  • Arvind Meena

      Affiliations

    • Department of Hematology
    • ,
  • Suhail Akhter

      Affiliations

    • Department of Hematology
    • ,
  • Vinita Sharma

      Affiliations

    • Department of Hematology
    • ,
  • Birendra Kumar Yadav

      Affiliations

    • Department of Hematology
    • ,
  • Madhuri Behari

      Affiliations

    • Department of Neurology
    • ,
  • Renu Saxena

      Affiliations

    • Department of Hematology
    • Corresponding Author InformationCorresponding author. Department of Hematology, I.R.C.H. Building (1st floor), All India Institute of Medical Sciences, Ansari Nagar, New Delhi – 110 029, India. Tel.: +91 011 26593642; fax: +91 011 26588663.

Received 29 September 2008 ,Revised 25 February 2009 ,Accepted 25 February 2009.

References 

  1. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke. 2000;31:3067–3078
  2. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem. 1995;270:4053–4057
  3. Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, et al Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factorVaR506Q by activated protein C. J Biol Chem. 1995;270:21158–21166
  4. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost. 1996;76:208–214
  5. Thorelli E, Kaufman RJ, Dahlback B. Cleavage of Factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood. 1999;93:2552–2558
  6. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–1508
  7. Williamson D, Brown K, Luddington R, Baglin C. Factor V Cambridge. A new mutation (Arg306 to Thr) associated with resistance to activated protein C. Blood. 1998;91:1140
  8. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998;91:1135
  9. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, et al A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997;90:1552–1557
  10. Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, et al Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost. 1996;75:45–48
  11. Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, et al Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost. 1997;77:329–331
  12. Cushman M. Inherited risk factors for venous thrombosis. Hematol Am Soc Hematol Educ Program. 2005;452–457
  13. Noe DA, Murphy PA, Bell WR, Siegel JN. Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits. Am J Physiol. 1989;257:R49–56
  14. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113:636–642
  15. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. May 18 2005;293:2352–2361
  16. Biswas A, Bajaj J, Ranjan R, Meena A, Akhter MS, Yadav BK, et al Factor V Leiden: Is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?. Clin Chim Acta. 2008;392:21–24
  17. Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem. 2001;276:4389–4397
  18. Graf LL, Welsh CH, Qamar Z, Marlar RA. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden". Am J Clin Pathol. 2003;119:52–60
  19. Lecumberri R, Ceberio I, Montes R, López ML, Alberca I, Rocha E, et al. "Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease". Haematologica. 2003;88:236–237
  20. Duran R, Biner B, Demir M, Celtik C, Karasalihoğlu S. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke. Clin Appl Thromb Hemost. 2005;11:83–88
  21. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, et al Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1999;100:736–742
  22. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 2000;83:10–13
  23. Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost. 1995;74:1198–1199

PII: S0049-3848(09)00160-1

doi: 10.1016/j.thromres.2009.02.015

Thrombosis Research
Volume 124, Issue 4 , Pages 397-402 , September 2009

Article Tools

* Image Usage & Resolution